Although platinum compounds (e.g., cisplatin) or PARP inhibitors (e.g., olaparib) have been approved by the FDA for the clinical treatment of breast cancer, the benefit is limited to patients with defective DNA repair systems, such as those harboring BRCA mutations. Here, PARP1 is linked to breast carcinoma.